Nifty14,867.35176.65

Adani Gas1,060.6599.4

FEATURED FUNDS

★★★★★

ICICI Prudential Midcap Direct Plan-Growth

ICICI Prudential Credit Risk Fund Direct Plan-Gr..

ICICI Prudential Smallcap Fund Direct Plan-Growt..

ICICI Prudential Asset Allocator Fund (FOF) Dire..

ICICI Prudential Large & Mid Cap Fund Direct Pla..

All about AstraZeneca COVID vaccine and concerns about it

Divya Rajagopal

, ET Bureau|

02 Apr 2021, 10:40 AM IST

1/5

The clotting factor

Countries such as Canada, Germany, Norway and Denmark have either restricted the use of the AstraZeneca/Oxford vaccine or have halted its use for those below a certain age following reports concerning blood clots. How severe are the clotting issues? Why do other countries including India continue to use and why the WHO is not alarmed?

AFP

2/5

Restrictions?

Health authorities in Canada and Germany have updated AstraZeneca/Oxford vaccine label, restricting their use. Its use is restricted to those under the age of 55.

AFP

3/5

Why the restriction?

Authorities found the vaccination caused extreme blood clots combined with low platelet count in a few patients along with bleeding. These adverse events have
been named as vaccineinduced prothrombotic immune thrombocytopenia (VIPIT).
These clots are in very rare cases seen to affect the nervous system.

New York Times

4/5

Why do regulators back vaccination?

The European Medicine Agency (EMA), World Health Organization, and Health Canada have acknowledged these rare adverse events. However, after a careful risk and
benefit analysis, EMA and WHO say vaccine benefits outweigh the risk.

5/5

Number of adverse events

The adverse events have primarily been reported in Europe and specifically in Germany. Most cases are women under the age of 55 years. Data shows that in Europe 1 in 1,000,000 at risk of this adverse even

AFP